Seeing Is Believing
Currently out of the existing stock ratings of Jeffrey Hung, 72 are a HOLD (43.64%), 15 are a SELL (9.09%), 78 are a BUY (47.27%).
Analyst Jeffrey Hung, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 59.08% that have a potential upside of 24.76% achieved within 138 days.
Jeffrey Hung’s has documented 335 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 07-Aug-2024.
Analyst best performing recommendations are on RYTM (RHYTHM PHARMACEUTICALS).
The best stock recommendation documented was for RYTM (RHYTHM PHARMACEUTICALS) at 11/9/2022. The price target of $26 was fulfilled within 2 days with a profit of $3.75 (16.85%) receiving and performance score of 84.27.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
23
$6.93 (43.12%)
30
30 days ago
0/3 (0%)
$7.28 (46.31%)
Buy
27
$10.93 (68.01%)
27
30 days ago
8/21 (38.1%)
$11.28 (71.76%)
119
Buy
20
$3.93 (24.46%)
28
1 months ago
16/21 (76.19%)
$4.83 (31.84%)
184
Buy
28
$11.93 (74.24%)
30
1 months ago
0/3 (0%)
$12.83 (84.57%)
Buy
28
$11.93 (74.24%)
37
1 months ago
25/36 (69.44%)
$12.83 (84.57%)
486
Which stock is Jeffrey Hung is most bullish on?
Which stock is Jeffrey Hung is most reserved on?
What Year was the first public recommendation made by Jeffrey Hung?